DEDN6526A / Roche - LARVOL DELTA

A study of DEDN6526A in patients with metastatic or unresectable melanoma (clinicaltrials.gov) - P1 , N=50; Not yet recruiting -> Recruiting; Start date: Feb 2012 -> Mar 2012; Completion date: Sep 2015 -> Oct 2015

Completion date • Enrollment open • Start date • Melanoma

A study of DEDN6526A in patients with metastatic or unresectable melanoma (clinicaltrials.gov) - P1, N=50; Sponsor: Genentech; Suspended -> Recruiting; Completion date: Dec 2012 -> May 2015.

Enrollment open • Melanoma

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. (PubMed, Invest New Drugs) - P1; "Conclusion DEDN6526A administered at the RP2D of 2.4 mg/kg q3w had an acceptable safety profile and showed evidence of anti-tumor activity in patients with cutaneous, mucosal, and uveal melanoma. ClinicalTrials.gov identifier: NCT01522664."

Clinical • Journal • P1 data